

107089146

JC13 Rec'd PCT/PTO 27 MAR 2002

TRANSMITTAL LETTER TO THE UNITED STATES

ATTORNEY'S DOCKET NUMBER 51748

DESIGNATED/ELECTED OFFICE (DO/EO/US)
CONCERNING A FILING UNDER 35 U.S.C. 371

U.S. APPLICATION NO. (If known, see 37 CFR 1.5)

INTERNATIONAL APPLICATION NO.	INTERNATIONAL FILING DATE	PRIORITY DATE CLAIMED
PCT/EP00/09671	2 October 2000	6 October 1999 24 December 1999 6 June 2000 14 June 2000 11 August 2000

TITLE OF INVENTION: INHIBITORS OF THE ENDOTHELIN SIGNALLING PATHWAY AND $\alpha_2\beta_3$ INTEGRIN RECEPTOR ANTAGONISTS FOR COMBINATION THERAPY

APPLICANT(S) FOR DO/EO/US Wilhelm AMBERG, Andreas KLING, Wilfried HORNBERGER

Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:

1. /X/ This is a FIRST submission of items concerning a filing under 35 U.S.C. 371.
 2. / / This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371.
 3. /X/ This express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and PCT Articles 22 and 39(1).
 4. /x / A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority date.
 5. /X/ A copy of the International Application as filed (35 U.S.C. 371(c)(2)).
 - a./X/ is transmitted herewith (required only if not transmitted by the International Bureau).
 - b./ / has been transmitted by the International Bureau.
 - c./ / is not required, as the application was filed in the United States Receiving Office (RO/USO).
 6. /X/ A translation of the International Application into English (35 U.S.C. 371(c)(2)).
 7. / / Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3)).
 - a./ / are transmitted herewith (required only if not transmitted by the International Bureau).
 - b./ / have been transmitted by the International Bureau.
 - c./ / have not been made; however, the time limit for making such amendments has NOT expired.
 - d./ / have not been made and will not be made.
 8. / / A translation of the amendments to the claims under PCT Article 19(35 U.S.C. 371(c)(3)).
 9. / / An oath or declaration of the inventor(s)(35 U.S.C. 371(c)(4)).
 - 10./ / A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).
- Items 11. to 16. below concern other document(s) or information included:
- 11./ / An Information Disclosure Statement under 37 CFR 1.97 and 1.98.
 - 12./ / An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.
 - 13./ A FIRST preliminary amendment.
/ / A SECOND or SUBSEQUENT preliminary amendment.
 - 14./ / A substitute specification.
 - 15./ / A change of power of attorney and/or address letter.
 - 16./x / Other items or information.
International Search Report

U.S. Appl. No. (If Known) INTERNATIONAL APPLN. NO.
PCT/EP00/09671

ATTORNEY'S DOCKET NO.
51748

		CALCULATIONS	PTO USE ONLY
17. /X/ The following fees are submitted			
BASIC NATIONAL FEE (37 CFR 1.492(a)(1)-(5)):			
Search Report has been prepared by the			
EPO or JPO.....	\$890.00	890.00	
International preliminary examination fee paid to USPTO			
(37 CFR 1.482).....	\$710.00		
No international preliminary examination fee paid to			
USPTO (37 CFR 1.482) but international search fee paid			
to USPTO (37 CFR 1.445(a)(2)).....	\$740.00		
Neither international preliminary examination fee			
(37 CFR 1.482) nor international search fee			
(37 CFR 1.445(a)(2)) paid to USPTO	\$ 1,040.00		
International preliminary examination fee paid to			
USPTO (37 CFR 1.482) and all claims satisfied pro			
-visions of PCT Article 33(2)-(4).....	\$100.00		
ENTER APPROPRIATE BASIC FEE AMOUNT = \$		890.00	
Surcharge of \$130.00 for furnishing the oath or declaration			
later than / / 20 / / 30 months from the earliest			
claimed priority date (37 CFR 1.492(e)).			
Claims	Number Filed	Number Extra	Rate
Total Claims	10 -20		X\$18.
Indep. Claims	3 -3		X\$84.
Multiple dependent claim(s)(if applicable)			+280.
TOTAL OF ABOVE CALCULATION		=	890.
Reduction of 1/2 for filing by small entity, if applicable.			
Verified Small Entity statement must also be filed			
(Note 37 CFR 1.9, 1.27, 1.28).			
SUBTOTAL		=	890.
Processing fee of \$130. for furnishing the English			
translation later than / / 20 / / 30 months from the			
earliest claimed priority date (37 CFR 1.492(f)). +			
TOTAL NATIONAL FEE		=	890 .
Fee for recording the enclosed assignment (37 CFR 1.21(h)).			
The assignment must be accompanied by an appropriate cover			
sheet (37 CFR 3.28, 3.31) \$40.00 per property =			
TOTAL FEES ENCLOSED		= \$	930.00
		Amount to be	
		refunded: \$	
		Charged \$	

a./X/ A check in the amount of \$ 930.00 to cover the above fees is enclosed.

b./ / Please charge my Deposit Account No. _____ in the amount of \$ _____ to cover the above fees. A duplicate copy of this sheet is enclosed.

c./X/ The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 11-0345. A duplicate copy of this sheet is enclosed.

NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b) must be filed and granted to restore the application to pending status.

SEND ALL CORRESPONDENCE TO:
KEIL & WEINKAUF
1101 Connecticut Ave., N.W.
Washington, D. C. 20036

SIGNATURE

Herbert B. Keil
NAME

Registration No. 18,967

Inhibitors of the Endothelin Signalling Pathway and $\alpha_v\beta_3$ Integrin receptor antagonists for Combination Therapy

- 5 The invention relates to the use of an endothelin blocker in combination with an $\alpha_v\beta_3$ integrin receptor antagonist for the treatment or prevention of diseases, particularly to the use of a pharmaceutical composition, comprising an endothelin blocker and an $\alpha_v\beta_3$ integrin receptor antagonist, for the treatment or prevention of cardiovascular disorders, particularly for the treatment or prevention of restenosis after vessel injury or revascularisation treatment and to the pharmaceutical composition itself.

- 15 Percutaneous transluminal coronary angioplasty (PTCA) was first introduced into the therapy of patients with coronary artery stenosis in the late seventies. In the two decades since this method has become the standard therapy for patients suffering from all forms of coronary artery disease. The success rate of the procedure itself has increased from 61 percent in the late seventies to well over 90 percent from the mid-eighties onwards. However, long-term success of PTCA remains limited by late restenosis caused by vessel wall proliferation that occurs in 20 to 40 percent of all patients to such an extent that a second PTCA is necessary [Anderson VH, Smalling RW, Serruys PW. Mechanical devices. In: 25 Willerson JT, Cohn JN (eds). Cardiovascular Medicine. New York, Edinburgh, London: Churchill Livingstone, 1995:617-651].

- As in the mid-90s about 500,000 primary PTCA procedures were carried out in the USA and about 200,000 in Europe, this accounts 30 for more than 230,000 patients per year eligible for a second invasive procedure due to recurrent angina. A hypothetical reduction of the incidence of restenosis by 10-15 percent per year would reduce annual treatment costs by almost 1.5 billion dollars in the USA and Europe alone.

- 35 Up to now a large number of clinical trials performed to investigate whether systemic administration of drugs which were effective in animal models of restenosis were efficacious in men have failed. The reason for this discrepancy between pre-clinical and 40 clinical studies could be that doses effective in experimental settings have not been applicable to patients due to other cardiovascular effects of these drugs [Pratt RE, Dzau VE. Pharmacological strategies to prevent restenosis. Circulation 1996;93:848-852].

Ursprüngliche Fassung
Nichts ändern!

Meanwhile revascularisation by balloon dilatation, stentimplantation, laser or rotablator are used not only in coronary arteries, but in all other large arteries accessible if atherosclerotic lesions make such an intervention necessary (Stenosis of renal
5 arteries, carotid arteries, femoral and brachial arteries). Thus the number of patients having problems with restenosis after any such intervention steadily increases posing a huge therapeutical and economic (reduction in health care costs) potential for drugs effectively inhibiting restenosis.

10

Endothelin (ET), a 21 amino acid peptide, has been described as the most potent endogenous vasoconstrictor known. [Yanagisawa M, Kurihara H, Kimura S, et al. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 1988;
15 332:411-415]. Its precursor is big-Endothelin, which is cleaved to ET by ECE (endothelin converting enzyme). ET binds in an autocrine/paracrine fashion to two different specific high affinity receptors, named ET_A and ET_B . Within the vasculature ET_A receptors are only located on smooth muscle cells (SMCs) leading to vaso-
20 constriction and SMC proliferation. In addition, a variable portion of ET_B receptors were also described on SMCs promoting at that location the same effect as ET_A receptors via the same intracellular signalling pathways [Rubanyi GM, Polokoff MA. Endothelins: Molecular biology, biochemistry, pharmacology, physiology,
25 and pathophysiology. Pharmacol Rev 1994;46:325-415].

It is known, that ET_A receptor antagonists effect on restenosis. The selective ET_A receptor antagonist A 127722 was tested in pigs with coronary artery stents [McKenna CJ, Burke SE, Opgenorth TJ,
30 et al., Selective ET_A receptor antagonism reduces neointimal hyperplasia in a porcine coronary stent model, Circulation 1998, 97, 2551-2556]. After 28 days of oral treatment (b.i.d.) a maximal reduction in neointima formation of about 30% has been reported.

35

Arterial injury after revascularisation also triggers the expression of vascular membrane-bound protein heterodimers called integrins especially of integrins $\alpha_v\beta_3$ and $\alpha_v\beta_5$ [Corjay MH, Diamond SM, Schlingmann KL, Gibbs SK, Stoltenborg JK, Racanelli AL. AlphaVbeta3, alphaVbeta5, and osteopontin are coordinately upregulated at early time points in a rabbit model of neointima formation. J Cell Biochem 1999;75:492-504] and it is known since 1994 that formation of neointimal hyperplasia as the leading cause of restenosis can be inhibited by antagonists to integrin $\alpha_v\beta_3$ [Choi
45 ET, Engel L, Callow AD, Sun S, Trachtenberg J, Santoro S, Ryan US. Inhibition of neointimal hyperplasia by blocking $\alpha_v\beta_3$ integrin

with a small peptide antagonist GpenGRGDSPCA J Vasc Surg 1994;19:125-134].

- First experimental hints came from the work of Sriramaraao and co-workers which could show that endothelial attachment and spreading as basic mechanisms of angiogenesis is mediated by integrins $\alpha_2\beta_1$ and $\alpha_v\beta_3$ and could be inhibited by the integrin $\alpha_v\beta_3$ specific antibody LM-609 and by RGD-containing peptides [Sriramaraao P, Mendler M, Bourdon M Endothelial cell attachment and spreading on human tenascin is mediated by alpha 2 beta 1 and alpha v beta 3 integrins. J Cell Science 1993;105:1001-1012].
- Based on the clinical success of the anti-platelet integrin $\alpha_{IIb}\beta_3$ antibody abciximab (c7E3 Fab, Reopro®) which led to sustained suppression of ischemic complications (endpoints death, MI or repeat intervention) after coronary interventions [Topol EJ, Ferguson JJ, Weisman HF, Tchong JE, Ellis SG, Kleiman NS, Ivanhoe RJ, Wang AL, Miller DP, Anderson KM, Califf RM. Long-term protection from myocardial ischemic events in a randomized trial of brief integrin beta3 blockade percutaneous coronary intervention. EPIC Investigator Group. Evaluation of Platelet IIb/IIIa Inhibition for Prevention of Ischemic Complication. JAMA 1997;278:479-84] and the finding that it has similar affinity to both integrin $\alpha_{IIb}\beta_3$ and $\alpha_v\beta_3$ [Tam SH, Sassoli PM, Jordan RE, Nakada MT. Abciximab (Reopro, chimeric 7E3 Fab) demonstrates equivalent affinity and functional blockade of glycoprotein IIb/IIIa and alpha(v)beta3 integrins. Circulation 1998;98:1085-1091] it was suspected that besides acute thrombosis abciximab was also able to prevent vascular restenosis.
- This anti-proliferative effect could be demonstrated in a porcine coronary injury model, where a selective integrin $\alpha_v\beta_3$ blockade by the peptidic compound XJ 735 potentially reduced neointimal hyperplasia by 43% and led to 2.9 fold less lumen stenosis [Srivatsa SS, Fitzpatrick LA, Tsao PW, Reilly TM, Holmes DR Jr, Schwartz RS, Mousa SA. Selective alpha v beta 3 integrin blockade potentially limits neointimal hyperplasia and lumen stenosis following coronary arterial stent injury: evidence for the functional importance of integrin alpha v beta 3 and osteopontin expression during neointima formation. Cardiovasc Res. 1997;36:408-28].
- In addition integrin $\alpha_v\beta_3$ antagonists have been shown to themselves exhibit some antithrombotic activity due to inhibition of $\alpha_v\beta_3$ -mediated platelet function like adhesion to the vessel wall [Gawaz M, Neumann FJ, Dickfeld T, Reininger A, Adelsberger H, Gebhardt A, Schomig A. Vitronectin receptor (alpha(v)beta3) mediates platelet adhesion to the luminal aspect of endothelial

cells: implications for reperfusion in acute myocardial infarction. Circulation. 1997;96:1809-18].

Both receptors, namely ET receptors and integrin $\alpha_v\beta_3$, play a role
5 in restenosis after vascular injury both in animal models and in man. By inhibiting either of the two principles, a 30 to 40 percent reduction of neointima formation could be achieved in the relevant experimental models.

10 It is an object of the present invention to provide an effective method of treatment or prevention of cardiovascular disorders, particularly of restenosis after revascularisation, with acceptable side effects and advantageous properties.

15 We have found that this object is achieved by using an endothelin blocker in combination with an $\alpha_v\beta_3$ integrin receptor antagonist.

By combining compounds which act as ET blockers and $\alpha_v\beta_3$ integrin receptor antagonist either in one formulation or as a kit-of-
20 parts combination by applying both separately via the same or different routes, it is possible to achieve a reduction of restenosis significantly more pronounced than one of the two treatments alone at the given doses. The combination of an ET blocker and an $\alpha_v\beta_3$ integrin receptor antagonist in doses too low to be
25 effective alone is as least as effective as a high mono-therapy with either agent and has less potential for side-effects than one principle alone.

Therefore, the invention relates to the use of an endothelin
30 blocker in combination with an $\alpha_v\beta_3$ integrin receptor antagonist for the manufacture of medicaments for the treatment or prevention of diseases, particularly of cardiovascular disorders, particularly of restenosis after vessel injury or revascularisation treatment.

35 Cardiovascular disorders are, for example, atherosclerosis, restenosis after vessel injury or revascularisation treatment, angioplasty (neointima formation, smooth muscle cell migration and proliferation), myokard infarkt or heart failure.

40 In a preferred embodiment, the combination according to the invention can be used for the manufacture of medicaments for the treatment or prevention of restenosis after vessel injury or revascularisation treatment.

According to the invention, restenosis preferred means the sum of angiographic end points and clinical events, i.e. late (30 days after intervention and later) proliferative thickening of the wall and loss of minimal lumen diameter (MLD) of the vessel subjected to angioplasty together with the clinical endpoints death, myocardial infarction and repeat intervention (PTCA).

Restenosis can occur after vessel injury or revascularisation treatment. Revascularisation treatment preferred means methods of percutaneous transluminal angioplasty (PTA), such as balloon dilatation, stent implantation, laser or rotablator. These methods are used not only in coronary arteries (percutaneous transluminal coronary angioplasty (PTCA)), but also in other large arteries accessible if atherosclerotic lesions make such an intervention necessary (Stenosis of renal arteries, carotid arteries, femoral and brachial arteries).

According to the invention, endothelin blocker means an inhibitor of the Endothelin Signalling Pathway such as, for example, endothelin receptor antagonists (ET antagonist), ECE inhibitors, antibodies against ET or ECE or modulators of expression of ET-precursor proteins or ET-receptors, particularly inhibitors of the Big-ET expression.

Preferred endothelin blockers are ET antagonists, ECE inhibitors, or Antibodies against ET or ECE, most preferred endothelin blockers are ET antagonist.

Preferred ECE Inhibitors within the scope of the invention are compounds which have a K_i value of $1\mu\text{M}$ or less. Most preferred are those ECE Inhibitors which have a K_i value of 100nM or less and mostly preferred are those ECE Inhibitors which have a K_i value of 10nM or less.

Suitable for the combination therapy of the invention are in principle all ECE inhibitors, for example peptidic and non-peptidic inhibitors, preferred are non-peptidic inhibitors, more preferred such which are orally available, such as

Pohosphoramidon;

CGS-31447: 1-[[[(1S)-2-[1,1'-biphenyl]-4-yl-1-(1H-tetrazol-5-yl)ethyl]amino]-3-(1-naphthyl)propylphosphonic acid;

CGS-34043: [[[(1S)-2-dibenzo[b,d]furan-3-yl-1-(1H-tetrazol-5-yl)ethyl]amino]methyl]phosphonic acid;

CGS-35066: (2S)-3-dibenzo[b,d]furan-3-yl-2-[(phosphonomethyl)amino] propanoic acid; CGS-35339: (2S)-3-dibenzo[b,d]furan-3-yl-2-[(diphenoxyphosphoryl)methyl] amino]propanoic acid;

- CGS-35066; WS-79089A: 1,6,9,14-tetrahydroxy-3-(2-hydroxypropyl)-7-methoxy-8,13-dioxo-5,6,8,13-tetrahydrobenzo[a]naphthacene-2-carboxylic acid; WS-75624A: (6-[2-(6-hydroxyheptyl)-1,3-thiazol-4-yl]-4,5-dimethoxy-2-pyridinecarboxylic acid);
- 5 PD-069185: N-(1-ethyl-3-piperidinyl)-6-iodo-2-(trichloromethyl)-4-quinazolinamine; SCH-54470: N-(1-(Hydroxy(1(R)-(N-alpha-(methylsulfonyl)-L-lysylamino)-2-phenylethyl)phosphinylmethyl)cyclopentylcarbonyl)-L-tryptophan dilithium salt; RU-69296: (2S)-2-([2-(3-bromobenzyl)-3-sulfanylpropanoyl]amino)-3-(1H-indol-3-yl)propanoic acid; RU-69739: (2S)-2-([2-(4-bromobenzyl)-3-sulfanylpropanoyl]amino)-3-(1H-indol-3-yl)propanoic acid; KC-12792-2-AB; SLV-306: ((3S,2'R)-3-(1-(2'-(Ethoxycarbonyl)-4'-phenyl-butyl)-cyclopentan-1-carbonylamino)-2,3,4,5-tetrahydro-2-oxo-1H-benzapin-1-acetic acid; FR-901533;

15

Preferred Endothelin receptor antagonists within the scope of the invention are substances which have a K_i value of $1\mu\text{M}$ or less for either the ET_A receptor or the ET_B receptor or for both receptors at the same time. Most Preferred are those endothelin receptor

- 20 antagonists which have a K_i value of 100nM or less and mostly preferred are those endothelin receptor antagonists which have a K_i value of 10nM or less. The K_i value of endothelin receptor antagonists can be measured as described in DE 19636046 A1.

- 25 Suitable endothelin receptor antagonists for the combination therapy of the invention are in principle all endothelin receptor antagonists, peptidic and non-peptidic antagonists, for example as described in WO 96/22978, WO 98/27070, WO 98/09953, EP 617001, WO 98/22482, WO 97/30045, WO 9963936, WO 9833780, WO 9854116,
- 30 WO9842709, WO 9841521, WO 9849162, WO 9717342, WO 9813366, WO 9739000, WO 9730045, WO 2000001389, WO 9937639, WO 9912916, WO 05132, WO 9728154, WO 9612706, WO 9827091, DE 19612101, DE 19609597, US 5716984, US 5939446, US 5922681, US 6048893 or GB 2337048, preferred are non-peptidic antagonists, more preferred
- 35 such which are orally available.

Examples for peptidic endothelin receptor antagonists are:


- FR-139317 (Perhydroazepine-1-ylcarbonyl-L-leucyl-(1-methyl)-D-tryptophyl-[3-(2-pyridyl)]-D-alanine); FR-901367 (2-Ac-
- 40 tamido-3-[[1,4,4a,5,6,6a,7,12,12a,12b-decahydro-4a,8,12a,12b-tetrahydroxy-3-methyl-1,7,12-trioxobenz[a]anthracene-6a-yl]thio]propionic acid); BE-18257B (Cyclo(-D-Trp-D-Glu-L-Ala-allo-D-Ile-L-Leu-)); BQ-123 (Cyclo(-D-Trp-D-Asp-L-Pro-
- 45 D-Val-L-Leu-)); TAK-044 (Cyclo(-4-oxo-4-(4-phenyl-1-piperazinyl)-L-2-aminobutanoyl-L-Asp-D-2-(2-thienyl)glycyl-L-Leu-D-Trp-D-Asp-) di-sodium salt); PD-142893 (N-Acetyl-(3,3-diphenyl-D-ala-

nine)-L-Leu-L-Asp-L-Ile-L-Ile-L-Trp); PD-156252 (N-Acetyl-2-D-(10,11-dihydro-5H-dibenzo(a,d)cycloheptene-5-yl)-glycyl-L-Leu-L-Asp-L-Ile-N-methyl-L-Ile-L-Trp disodium salt); BQ-485 (Perhydroazepin-1-ylcarbonyl-L-leucyl-D-tryptophyl-D-tryptophan);
 5 Cochinnicin I or Myricerone caffeic acid ester.

Examples for non-peptidic ET receptor antagonists are:

- Sitaxsentan (N-(4-Chloro-3-methylisoxazol-5-yl)-2-(2-(6-methyl-3,4-methylenedioxy-1-yl)acetyl)thiophen-3-sulfonamide);
 10 TBC-3214 (N-(2-acetyl-4,6-dimethylphenyl)-3-[(4-chloro-3-methyl-5-isoxazolyl)amino]sulfonyl)-2-thiophenecarboxamide);
 TBC-3711; SB-209670 ((1S,2R,3S) 1-(3,4-methylenedioxyphenyl)-3-(2-(carboxymethoxy)-4-methoxyphenyl)-5(prop-1-yloxy)indan-2-carboxylic acid); Bosentan (4-tert-Butyl-N-(6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)(2,2'-bipyrimidin)-4-yl)benzene-sulfonamide); PD-156707 (2-(3,4-Methylenedioxyphenyl)-4-(4-methoxyphenyl)-4-oxo-3-(3,4,5-trimethoxybenzyl)-but-2-ene acid sodium salt); L-749329 (4-(2-(4-Isopropylphenylsulfonamido)-1-(3,4-methylenedioxyphenyl)-2-oxoethoxy)-3-propylbenzoic acid); L-754142
 20 (4-(2-(4-Isopropylphenylsulfonamido)-1-(3,4-methylenedioxyphenyl)-2-oxoethoxy)-3-propylbenzoic acid dipotassium salt); Enrasentan ((1S,2R,3S) 1-(3,4-Methylenedioxyphenyl)-3-(2-(2-hydroxyethoxy)-4-methoxyphenyl)-5(prop-1-yloxy)indan-2-carboxylic acid);
 25 A-127722 (trans-trans-2-(4-methoxyphenyl)-4-(3,4-methylenedioxyphenyl)-1-(2-(N,N-dibutylamino)-2-oxoethyl)-pyrrolidine-3-carboxylic acid); Abtrasentan (ABT-627 ([2S-(2a,3b,4a)]-2-(4-methoxyphenyl)-4-(3,4-methylenedioxyphenyl)-1-(2-(N,N-dibutylamino)-2-oxoethyl)-pyrrolidine-3-carboxylic acid)); EMD-94246
 30 (N-(2,1,3-Benzothiadiazol-5-yl)-5-(dimethylamino)naphthalin-1-sulfonamide potassium salt); ZD-1611 (3-(4-(3-(N-(3-Methoxy-5-methylpyrazin-2-yl)sulfamoyl)pyridin-2-yl)phenyl)-2,2-dimethylpropionic acid); K-8794 (N-(2,6-dimethylphenyl)-3-(6-(4-tert-butylphenylsulfonylamino)-5-(2-methoxyphenoxy)-2-(2-pyrimidinyl)-4-pyrimidinyl)propionamide);
 35 A-182086 ((2a,3b,4a)-2-(3-Fluor-4-methoxyphenyl)-4-(3,4-methylenedioxyphenyl)-1-(2-(pentylsulfonyl)propyl-amino)ethyl-pyrrolidine-3-carboxylic acid); PD-163070 ((2Z)-2-(1,3-benzodioxol-5-yl)-3-[3-(dimethylamino)benzyl]-4-(4-methoxyphenyl)-4-oxo-2-butenic acid sodium salt); PD-166557 ((2Z)-3-(3-aminobenzyl)-2-(1,3-benzodioxol-5-yl)-4-(4-methoxyphenyl)-4-oxo-2-butenic acid sodium salt); Ro-61-1790 (N-{6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-2-[2-(1H-tetrazol-5-yl)-4-pyridinyl]-4-pyrimidinyl}-5-methyl-2-pyridinesulfonamide disodium salt)
 45 BMS-193884 (N-(3,4-dimethyl-5-isoxazolyl)-4'-(1,3-oxazol-2-yl)[1,1'-biphenyl]-2-sulfonamide); BMS-207940; SB-209598 (3-[2-(carboxymethoxy)-4-methoxyphenyl]-1-[(6-chloro-1,3-benzo-

dioxol-5-yl)methyl]-1*H*-indole-2-carboxylic acid); SB-209834 ((2*E*)-2-(1,3-benzodioxol-5-ylmethyl)-3-(2-butyl-1-methyl-1*H*-imidazol-5-yl)-3-[2-(carboxymethoxy)-4-methoxyphenyl]-2-propenoic acid); A-206377 ((2*S*,3*R*,4*S*)-4-(1,3-benzodioxol-5-yl)-1-[2-(dibutylamino)-2-oxoethyl]-2-[2-(2-oxo-1-pyrrolidinyl)ethyl]-3-pyrrolidinecarboxylic acid); EMD-122801 ((2*Z*)-2-(2,1,3-benzothiadia-
 5 zol-5-yl)-4-(4-methoxyphenyl)-4-oxo-3-(3,4,5-trimethoxybenzyl)-2-butenic acid sodium salt); Tezosentan (N-{6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-2-[2-(1*H*-tetraazol-5-yl)-4-pyridi-
 10 nyl]-4-pyrimidinyl}-5-isopropyl-2-pyridinesulfonamide disodium salt); AC-61-0612(N-{6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-2-[2-(1*H*-tetraazol-5-yl)-4-pyridinyl]-4-pyrimidinyl}-5-iso-
 propyl-2-pyridinesulfonamide); T-0201 (N-[6-{2-[5-bromo-2-pyrimidinyl)oxy]ethoxy}-5-(4-methylphenyl)-4-pyrimidinyl]-4-(2-hy-
 15 droxy-1,1-dimethylethyl)benzenesulfonamide sodiumsalt); J-104132 ((5*S*,6*R*,7*R*)-5-(1,3-benzodioxol-5-yl)-2-butyl-7-{2-[(2*S*)-2-carboxypropyl]-4-methoxyphenyl}-6,7-dihydro-5*H*-cyclopenta[*b*]pyri-
 dine-6-carboxylic acid) and compounds of the general formula I:



I

30

wherein R^1 , R^2 and R^3 are:

R^1 C_1 - C_4 -Alkyl, C_1 - C_4 -Alkoxy;

35 R^2 C_1 - C_4 -Alkyl, C_1 - C_4 -Alkoxy;

R^3 C_1 - C_8 -Alkyl which may carry a phenyl which may carry up to 2 identical or different C_1 - C_4 -Alkoxy radicals.

40 Preferred compounds of the formula I are compounds, wherein R^1 , R^2 and R^3 are

R^1 C_1 - C_2 -Alkyl, C_1 - C_2 -Alkoxy;

45 R^2 C_1 - C_2 -Alkyl, C_1 - C_2 -Alkoxy;

R³ C₁-C₂-Alkyl which may carry a phenyl which may carry up to 2 identical or different C₁-C₂-Alkoxy radicals.

Orally available ET-receptor antagonists are listed, for example, in Douglas, S. A., Trends in Pharmacol. Sci., 18, 408-12, 1997, preferred are ABT-627, A-182086, PD163070, PD166557, Bosentan, TBC-11252 or ZD-1611.

Most preferred ET antagonists are

- 10 (S)-2-(4,6-Dimethoxy-pyrimidin-2-yloxy)-3-methoxy-3,3-diphenylpropionic acid,
- (S)-2-(4,6-Dimethyl-pyrimidin-2-yloxy)-3-(2-(3,4-dimethoxyphenyl)ethoxy)-3,3-diphenylpropionic acid,
- (S)-2-(4,6-Dimethyl-pyrimidin-2-yloxy)-3-methoxy-3,3-diphenylpropionic acid or
- 15 (S)-2-(4,6-Dimethyl-pyrimidin-2-yloxy)-3,3-diphenylbutanoic acid.

Preferred $\alpha_v\beta_3$ integrin receptor antagonists within the scope of the invention are substances which show an IC₅₀ value of 100nM or less for the inhibition of vitronectin binding to integrin $\alpha_v\beta_3$ in an ELISA assay, which is, described for example in DE 19919218.9 (German application number).

Suitable $\alpha_v\beta_3$ integrin receptor antagonists for the combination therapy of the invention are, in principle, all $\alpha_v\beta_3$ integrin receptor antagonists, for example as described in Pitts et al.; J. Med. Chem. 2000, 43, 27-40; Batt et al., J. Med. Chem. 2000, 43, 41-51; Miller et al., Bioorg. Med. Chem. Lett. 9, 1999, 1807-1812; Keenan et al., Bioorg. Med. Chem. Lett. 9, 1999, 1801-1806; Rockwell et al., Bioorg. Med. Chem. Lett. 9, 1999, 937-942; Samanen et al., Current Pharm. Design 1997, 3, 545-584; Miller et al., J. Med. Chem. 2000, 43, 22-26; Hartmann and Duggan, Exp. Opin. Invest. Drugs 2000, 9 (6), 1281-1291; Miller et al., Drug Discovery Today 2000, 5 (9), 397-408; DE 19919218.9 (German application number), DE 19948269.1 (German application number), DE 19962998.6 (German application number), DE 10027514.1 (German application number), DE 10028575.9 (German application number), DE 10039998.3 (German application number), WO 9952879, WO 9835917, WO 0000486, WO 0017197, WO 0031067, WO 9843962, WO 9926945, WO 9950249, WO 9958162, WO 0000481, US 6056958, WO 43787, WO 9637492, WO 9723480, WO 9733887, WO 9748395, WO 9748444, WO 9823608, US 5,849,736, DE 19626701, EP 0796855A1, DE 19653645, DE 19653646, DE 19653647, EP 796855, EP 820988, EP 820991, EP 853084, EP 854145, US 5990145, WO 9915506, WO 9915507, WO9932457, WO 9937621, WO 9959992, EP 928790, EP 928793, US 6001855, WO 00024724, WO 9825892, WO 9965944, WO 0048603, WO 9938849, WO 9952872, DE 19534016, DE 19548709, DE 19653036, DE

10

- 19654483, DE 19705450, DE 1971300, DE 19725368, DE 19842415, DE 19850131, EP 683173, EP 710657, EP 741133, EP 771 818, WO 9714716, WO 9723451, WO 9738009, WO 9744333, WO 9800395, WO 9818764, WO 9827112, WO 9835949, WO 9901472, WO 9910371, WO 9931126, WO 0003973, WO 0026212, WO 9532710, WO 9726250, WO 9737655, WO 9808518, WO 9808840, WO 9818460, WO 9818461, WO 9831359, WO 9844797, WO 9846220, WO 9901472, WO 9930709, WO 9930713, WO 9931061, WO 9931099, WO 0006169, WO 0009503, US 5981546, US 6017925, US 6017926, WO 9967230, WO 9734865, FR 2768734-A1, FR 2768736-A1, WO 0032578, US 5639765, US 5681820, US 5852210, US 5972986, US 6013651, WO 9708145, WO 9736858, WO 9736859, WO 9736860, WO 9736861, WO 9736862, WO 9944985, WO 9944994, WO 9951638, WO 9952896, WO 0009143, WO 0038665, WO 0038715, WO 0038719, WO 0038786, WO 9600574, WO 9600730, WO 9606087, WO 9626190, WO 9701540, WO 9724119, WO 9724122, WO 9724124, WO 9724336, WO 9814192, WO 9815278, WO 9829561, WO 9830542, WO 9840488, WO 9905107, WO 9906049, WO 9911626, WO 9915170, WO 9915178, WO 9915508, WO 9945927, WO 0007544, WO 0033838 or WO 9933798, particularly, the following proteins, peptidic and nonpeptidic compounds.

Proteins and peptidic $\alpha_v\beta_3$ integrin receptor antagonists:

- LM 609 (vitaxin, Pharmaprojects),
 25 abciximab (c7E3 Fab, Reopro®, Pharmaprojects),
 Peptides and peptidomimetics of Arg-Gly-Asp and derivatives thereof like:
 cyclo(RGDfV), As-Pen-RGDC-OH, cyclo[RGD-Mamb-P], XJ 735
 (cyclo[R-G-D-Mamb-A]), XK 002 (cyclo[(NMe)R-G-D-
 30 (2-amino-1,3-thiazol-4-yl-acetic acid)-V]), DMP 728
 (cyclo[[(NMe)R-G-D-Mamb-DAbu]), SK+F 107260
 Mba-(NMe)R-Gly-Asp-Man
 | |
 S ————— S
 35 EMD 121974 (cyclo[R-G-D-f-(NMe)V]) and any other RGD containing peptides.

Non-peptidic $\alpha_v\beta_3$ integrin receptor antagonists:

- 40 (2R)-2-[(2R)-2-{3-[(3-{[amino(imino)methyl]amino}propanoyl)amino]phenyl}-3-carboxy propanoyl)amino]-3-methylbutanoic acid, 3-[8-(2-{[amino(imino)methyl]amino}ethyl)-1-benzyl-2-oxo-1,2,3,5-tetrahydro-4H-1,4-benzodiazepin-4-yl]propanoic acid, 2,3-dihydroxypropyl 2-[(benzyloxy)carbo-
 45 nyl]amino}-4-[(9,10-dimethoxy-4-(E)-2-(1,4,5,6-tetrahydropyrimidin-2-yl)hydrazono]-1,2,3,3a,4,5,6,10b-octahydrobenzo[e]azulen-8-yl)oxy]butanoate, (2S)-2-[(benzyloxy)carbo-

- nyl]amino}-3-[(4S)-4-[3-(4,5-dihydro-1H-imidazol-2-ylamino)propyl]-2,5-dioxoimidazolidin-1-yl]acetyl]amino]propanoic acid, L-7418415 ((2S)-2-[(phenylsulfonyl)amino]-3-[(4-[2-(1,4,5,6-tetrahydropyrimidin-2-ylamino)ethoxy]benzoyl)amino]propanoic acid),
- 5 (2S)-2-[(4-isobutylphenyl)sulfonyl]amino}-3-[(5-[3-(pyridin-2-ylamino)propyl]-4,5-dihydroisoxazol-3-yl]carbonyl]amino]propanoic acid, (2S)-2-[(benzyloxy)carbonyl]amino}-3-[(4-[4-(4,5-dihydro-1H-imidazol-2-ylamino)butanoyl]piperazin-1-yl]carbonyl]amino]propanoic acid, (2S)-2-[(benzyloxy)carbonyl]amino}-3-[(4-[4-(4,5-dihydro-1H-imidazol-2-ylamino)propanoyl]piperazin-1-yl]carbonyl]amino]propanoic acid, SD-186 ((2S)-2-[(phenylsulfonyl)amino]-3-[(8-(pyridin-2-ylamino)methyl)-1-oxa-2-aza-spiro[4.5]dec-2-en-3-yl]carbonyl]amino]propionic acid), SD-183 ((2S)-2-[(phenylsulfonyl)amino]-3-[(8-(pyridin-2-ylamino)methyl)-1-oxa-2-azaspiro[4.5]dec-2-en-3-yl]carbonyl]amino]propanoic acid, SD-983 ((2S)-2-[(benzyloxy)carbonyl]amino}-3-[(3-[3-(4,5-dihydro-1H-imidazol-2-ylamino)propoxy]isoxazol-5-yl]carbonyl]amino]propanoic acid), XT-199 ((2S)-3-[(3-[3-(4,5-dihydro-1H-imidazol-2-ylamino)propoxy]isoxazol-5-yl]carbonyl]amino]-2-[(phenylsulfonyl)amino]propanoic acid), SG-545 (Methyl (2S)-2-[(benzyloxy)carbonyl]amino}-3-[(3-[3-(4,5-dihydro-1H-imidazol-2-ylamino)propoxy]isoxazol-5-yl]carbonyl]amino]propanoic acid), SM 256 ((2S)-3-[(1-[3-(1H-imidazol-2-ylamino)propyl]-1H-indazol-5-yl]carbonyl]amino]-2-[(mesitylsulfonyl)amino]propanoic acid), SD-836 (Pharmaprojects), SD-7784 (Pharmaprojects), SD-7783 (Pharmaprojects), S-137 (N-([1-(4-([amino(imino)methyl]amino)butyl]vinyl]amino)acetyl)-3-pyridin-3-yl-beta-alanine), S-787 (Seattle et al.; 21st Ann. Meet. Amer. Soc. Bone Mineral Res., 30.9.-4.10.1999; SU 410), S 448 (N-([3-([amino(imino)methyl]amino)benzoyl]amino]acetyl)-3-phenyl-beta-alanine), SC 68448 (N-([3-([amino(imino)methyl]amino)benzoyl]amino]acetyl)-3-(3,5-dichlorophenyl)-beta-alanine), SC 56631 (N-([5-([amino(imino)methyl]amino)pentanoyl]amino]acetyl)-3-pyridin-3-yl-beta-alanine), SC 69000 (4-[(3-([amino(imino)methyl]amino)benzoyl]amino]-N-(isobutoxycarbonyl)phenylalanine), SC-65811 (N-([3-([(benzylamino)carbonyl]amino)benzoyl]amino]acetyl)-3-pyridin-3-yl-beta-alanine), SB 223245 ((2S)-7-[(1H-benzimidazol-2-ylmethyl)(methyl)amino]carbonyl)-4-methyl-3-oxo-2,3,4,5-tetrahydro-1H-1,4-benzodiazepin-2-yl]acetic acid), SB 265123 [(10S)-3-[3-(pyridin-2-yl-amino)propoxy]-10,11-dihydro-5H-dibenzo[a,d]-cyclohepten-10yl]acetic acid), SB 267268 [(4S)-3-oxo-8-[3-(pyridin-2-ylamino)propoxy]-2-(2,2,2-trifluoroethyl)-2,3,4,5-tetrahydro-1H-2-benzazepin-4-yl]acetic acid), SB 273005 (Lark et al.; 21st Ann. Meet. Amer. Soc. Bone Mineral Res., 30.9.-4.10.1999; SU201), CP-4632

12

((2S)-3-[(3-fluoro-4-[4-(1,4,5,6-tetrahydropyrimidin-2-ylamino)piperidin-1-yl]benzoyl)amino]-2-[(phenylsulfonyl)amino]propanoic acid), (2S)-3-[(3-chloro-4-[4-(1,4,5,6-tetrahydropyrimidin-2-yl)piperidin-1-yl]benzoyl)amino]-2-[(phenylsulfonyl)amino]propanoic acid), SH306 (2S)-2-[(mesitylsulfonyl)amino]-3-[(1-[3-(pyridin-2-ylamino)propyl]-1H-indazol-5-yl]carbonyl)amino]propanoic acid, SB 273005 (Lark et al.; 21st Ann. Meet. Amer. Soc. Bone Mineral Res., 30.9.-4.10.1999; SU201) [(4S)-8-{2-[6-(Methylamino)pyridin-2-yl]ethoxy}-3-oxo-2-(2,2,2-trifluoroethyl)-2,3,4,5-tetrahydro-1H-2-benzazepin-4-yl]acetic acid, SC 72115 (3-(5-bromo-3-chloro-2-hydroxyphenyl)-N-([3-(4,5-dihydro-1H-imidazol-2-ylamino)benzoyl]amino)acetyl)-beta-alanine).

15 Preferred are non-peptidic antagonists, particularly those which are orally available and $\alpha_v\beta_3$ integrin receptor antagonists selected from the group:

LM 609 (vitaxin), EMD 121974 (cyclo[R-G-D-f-(NMe)V]), L-7418415 ((2S)-2-[(phenylsulfonyl)amino]-3-[(4-[2-(1,4,5,6-tetrahydropyrimidin-2-ylamino)ethoxy]benzoyl)amino]propanoic acid), SB 265123 [(10S)-3-[3-(pyridin-2-yl-amino)propoxy]-10,11-dihydro-5H-dibenzo[a,d]-cyclohepten-10yl]acetic acid), SB 267268 [(4S)-3-oxo-8-[3-(pyridin-2-ylamino)propoxy]-2-(2,2,2-trifluoroethyl)-2,3,4,5-tetrahydro-1H-2-benzazepin-4-yl]acetic acid), SB 273005 (Lark et al.; 21st Ann. Meet. Amer. Soc. Bone Mineral Res., 30.9.-4.10.1999; SU201), SC 68448 (N-[(3-[(amino(imino)methyl]amino)benzoyl)amino]acetyl)-3-(3,5-dichlorophenyl)-beta-alanine), SC 69000 (4-[(3-[(amino(imino)methyl]amino)benzoyl)amino]-N-(isobutoxycarbonyl)phenylalanine and SC-65811 (N-[(3-[(benzylamino)carbonyl]amino)benzoyl]amino]acetyl)-3-pyridin-3-yl-b-alanine).

All mentioned compounds can also be applied as prodrugs. Prodrugs are substances which metabolise in vivo to the active compound. Examples for such metabolism are first pass metabolism (e.g. esters to free acids or carboxylates).

All mentioned compounds may be administered as such or in the form of their salts with physiologically tolerated acids or bases.

40

Preferred combinations of an endothelin blocker with an $\alpha_v\beta_3$ integrin receptor antagonist are selected from the preferred endothelin blockers and the preferred $\alpha_v\beta_3$ integrin receptor antagonists.

45

13

In a further preferred embodiment, orally available ET antagonists are combined with orally available $\alpha_v\beta_3$ integrin receptor antagonists.

- 5 "Orally available" means at least 10%, preferred 20% and more preferred 30% for ET antagonists and 30%, preferred 50% and more preferred 70% for $\alpha_v\beta_3$ integrin receptor antagonist. The oral availability is for the purpose of this invention defined as measured in dogs as described in WO 9806740.
- 10 The endothelin blocker in combination with the $\alpha_v\beta_3$ integrin receptor antagonist may be administered together in a pharmaceutical composition or simultaneous via separate ways or separate or temporal graduated.
- 15 Therefore, the invention further relates to a pharmaceutical composition, comprising an endothelin blocker and an $\alpha_v\beta_3$ integrin receptor antagonist.
- 20 This composition can be used as a medicament, particularly for curing or preventing cardiovascular disorders, such as atherosclerosis, restenosis after vessel injury or revascularisation treatment, angioplasty (neointima formation, smooth muscle cell migration and proliferation), myokard infarkt or heart failure.
- 25 In a preferred embodiment, the composition is used for the treatment or prevention of restenosis after vessel injury or revascularisation treatment.
- 30 The compounds of the invention can be administered orally or parenterally in a conventionally way (subcutaneously, intravenously, intramuscularly, intraperitoneally, rectally). Administration can also take place with vapours or sprays through the nasopharyngeal space. Oral administration is preferred.
- 35 The dosage depends on age, condition and weight of the patient and on the mode of administration. The two compounds can be formulated in a single pharmaceutical form or in separate pharmaceutical forms. Administration can be given in several single doses
- 40 (e.g. 2 to 4) or once or twice a day as depot form.
- The weight ratio of $\alpha_v\beta_3$ integrin receptor antagonist to endothelin blocker conveniently is in the range of 1:100 to 100:1 preferably 1:10 to 10:1.
- 45 Advantageously, the dosage to be administered by means of a combination per day and kg amounts to 0,05 to 20 mg of an $\alpha_v\beta_3$ integrin receptor antagonist and 0,1 to 50 mg of an endothelin blok-

ker. In general, the total amount of an $\alpha_v\beta_3$ integrin receptor antagonist and an endothelin blocker to be administered daily amounts per kg to a maximum of 50 mg. When a hydrate or a pharmaceutically usable salt is used, then the above values are to be
5 appropriately adjusted.

The compounds can be used individually or together in conventional solid or liquid pharmaceutical forms, e.g. as uncoated or (film-)coated tablets, capsules, powders, granules, suppositories,
10 ries, solutions, ointments, creams or sprays. These are produced in a conventional way. In these, the active substances can be processed with conventional pharmaceutical aids such as tablet binders, fillers, preservatives, tablet disintegrants, flow regulators, plasticizers, wetting agents, dispersants, emulsifiers,
15 solvents, release slowing agents, antioxidants and/ or propellant gases (cf. H. Sucker et al. Pharmaceutische Technologie, Thieme Verlag, Stuttgart, 1978). The administration form obtained in this way normally comprises the active substance in an amount of from 0.1% to 99% by weight.

20 Treatment of a patient with a cardiovascular disease by a combination, composition and method according to the present invention may include concomitant use of further adjunctive agents, such as antiplatelet agents, e.g., aspirin, and anticoagulant agents,
25 e.g., heparin or low molecular weight heparin, or other drugs, e.g., β -blockers, angiotensin converting enzyme inhibitors, agents against reperfusion injury and others.

Subject of the present invention are also pharmaceutical compositions,
30 tions, comprising $\alpha_v\beta_3$ integrin receptor antagonist in an appropriate container and an endothelin blocker in a separate container to be used according to the above-mentioned administration regimens.

35 Pharmaceutical packaging units prepared in accordance with the present invention may consist of an appropriate administration form comprising the $\alpha_v\beta_3$ integrin receptor antagonist, and an appropriate packaging unit comprising the endothelin blocker. The two active compounds are preferably present in the packaging
40 unit in two different containers, e.g. tablets. However, depending on the type of active compound, it may also be possible to provide both compounds in a single dosage form. Further, the pharmaceutical packaging units comprise instructions, for example in the form of a package leaflet prescribed for medicaments from
45 which it follows that the administration of a therapeutically active amount of the $\alpha_v\beta_3$ integrin receptor antagonist advanta-

15

geously takes place in combination with administration of an endothelin blocker.

If applied separately, the administration of the endothelin blocker takes places before, simultaneously or after the administration of the $\alpha_v\beta_3$ integrin receptor antagonist.

Information regarding the manner of use can either be given in the information leaflet or as a packing overprint on the medical preparation which can be bought together with medicinal preparations which comprise $\alpha_v\beta_3$ integrin receptor antagonists. On the one hand, pharmaceutical packaging units comprising only appropriate administration forms of the $\alpha_v\beta_3$ integrin receptor antagonists can comprise such information e.g. in the form of package leaflets, wherein the combined administration together with endothelin blockers according to the present invention is mentioned. On the other hand, pharmaceutical packaging units comprising only endothelin blockers can comprise such information wherein the combined administration together with $\alpha_v\beta_3$ integrin receptor antagonists and the use according to the present invention is mentioned. A third alternative would be to provide pharmaceutical packaging units comprising an $\alpha_v\beta_3$ integrin receptor antagonist, endothelin blocker and an appropriate information about the combined use of both, e.g. the usual package leaflet.

Therefore, the invention further relates to a pharmaceutical trade package, comprising as pharmaceutical agent an endothelin blocker or/and an $\alpha_v\beta_3$ integrin receptor antagonist together with an instruction for use of this pharmaceutical agents in combination for simultaneous, separate, or temporal graduated application for the treatment or prevention of diseases.

Appropriate directions of use of the above-mentioned pharmaceutical agents are essential for commercialization of such pharmaceutical packages, comprising either the $\alpha_v\beta_3$ integrin receptor antagonist, endothelin blocker or a combination thereof.

Commercialization of appropriate pharmaceuticals by pharmaceutical companies is only possible when prior approval of such pharmaceutical agents and the respective administration regimens is achieved by the respective national Health Authorities, such as the FDA in the US or the CPMP Authority in Europe.

This includes but is not limited to performing clinical trials according to well-established procedures under the supervision of said pharmaceutical company which lateron intends to commercialize such pharmaceutical agents. This also includes filing of ap-

appropriate documentation about the results of such clinical trials with the respective Health Authority in order to get marketing approval. The approval is in many cases restricted to certain administration protocols or regimens which have to be included in printed form in the accompanying information leaflet prescribed for medicaments.

Examples

10 Example 1

Integrin $\alpha_v\beta_3$ (human)/ Vitronectin (human) ELISA:
96-well plates (Costar, cat # 3369) were coated overnight at 4°C with 100 μ l/well integrin $\alpha_v\beta_3$ (5 μ g/ml) from human placenta in 50 mmol/l NaHCO_3 (pH 9.2). After (3x) washing with 0.05% Tween 20 in PBS, 50 μ l of test buffer (0.1 % skimmed milk powder in 50 mmol/l Tris, 1 mmol/l CaCl_2 , 1 mmol/l MgCl_2 , 10 μ mol/l MnCl_2 , 100 mmol/l NaCl, 0.2% Tween 20) were pipetted into each well followed by 1 μ l DMSO (control) or 1 μ l $\alpha_v\beta_3$ integrin receptor antagonist solution (1 mmol/l to obtain a final test concentration of 10 μ mol/l) and by 50 μ l vitronectin solution (2 μ g/ml from human plasma. The wells were incubated for 2 h at room temperature and then washed again three times with 0.05% Tween 20 in PBS. Bound vitronectin was detected by incubation with 100 μ l of peroxidase-coupled anti-vitronectin antibodies (0.5 μ g/ml) in buffer containing 0.2 % Tween 20 and 0.1% milk powder for 2 h at room temperature. After three washing steps with 0.05% Tween 20 in PBS, TMB solution 100 μ l/well was added and incubated for 40 seconds at 37 °C. The reaction was stopped by addition of 100 μ l/well 2N H_2SO_4 . Finally the absorbance as a measure for bound vitronectin was measured in a microplate photometer at 450 nm.

Example 2

Cellular Adhesion Assay (ELISA technique):
24-well plates were coated overnight at 4°C with human vitronectin 50 ng/well in 50 mmol/l NaHCO_3 pH 9.2. After washing with CHO-S-SFMII medium the wells were incubated for 1 h at 37 °C with recombinant CHO $\alpha_v\beta_3$ expressing cells (subtype avb3-A: clone X, subtype $\alpha_v\beta_3$ -B: clone 5, subtype avb3-C: clone 18) in CHO-S-SFMII medium (Gibco 12052-015) at a concentration of $1 \cdot 10^6$ cells/ml with $\alpha_v\beta_3$ integrin receptor antagonist added to obtain final concentrations between 0.1 nmol/l and 10 μ mol/l for 2-3 h at 37 °C. Plates then again were washed four times with CHO-S-SFMII medium. XTT (Roche 1465015) 500 μ l/well in CHO-S-SFMII medium was added and incubated for 2-5 h at 37 °C. Finally the absorbance as a measure for the count of adhesive cells was measured in a photometer at 450 nm.

Example 3
HASMC Migration Assay

The migration of the primary human aortic SMC's was performed using 24-well Transwell cell culture chambers with an 8 μ m pore size polycarbonate membrane (Costar3422). The lower surface of the filter was coated with vitronectin or osteopontin by incubation with 600 μ l DMEM / 0.2% albumin / \pm integrin $\alpha_v\beta_3$ -ligand (10 μ g/ml); 3 hrs 37°C/5% CO₂. HASMC (Cascade Biologics; C-007-5C) were suspended in DMEM and 100 μ l were placed in the upper compartment of the chamber (250-300000 cells/well) with or without $\alpha_v\beta_3$ integrin receptor antagonist at various concentrations. The incubation was carried out at 37°C/5% CO₂ for 24 hours. The non-migrated cells on the upper surface of the filter were removed by washing with PBS. The filters were transferred to a new 24-well plate and the lower compartments were incubated with 400 μ l DMEM and 200 μ l XTT (Roche 1465015) at 37°C/5% CO₂. After 24 hours the absorbance of 100 μ l was measured at 450 nm.

Example 4
huCASM Proliferation Assay

Cryopreserved primary human coronary artery smooth muscle cells (huCASCs) were purchased from Clonetics® Cell Discovery Systems (catalog no. CC-2583). Cells were subcultured in T-75 flasks using smooth muscle cell growth medium-2 (SmGM-2) supplemented with 0.5 ng/ml recombinant human epidermal growth factor (hEGF), 5 % foetal bovine serum, 5 μ g/ml insulin, 50 μ g/ml Gentamicin / 50 ng/ml Amphotericin-B and human fibroblast growth factor-B (hFGF-B) 2 ng/ml (Clonetics® Cell cat. no. CC-3182). For the proliferation assay cells between passage 5-8 were seeded at 5000 cells/well in 96 well plates in a volume of 0.1 ml and allowed to attach for 24 hours. Thereafter proliferating cells were incubated with an endothelin blocker and/or an $\alpha_v\beta_3$ integrin receptor antagonist each at a concentration of 10⁻⁷M for further 24 hrs. Cell proliferation was quantitated in quadruplicates 24 hrs later using a colorimetric cell proliferation ELISA (BrdU, Roche Diagnostics, cat. no. 1 647 229).

In vivo study

Example 5
Pig Model of Coronary Artery Restenosis

The pig coronary restenosis models is acknowledged as the only preclinical animal model with predictive value for the human pathology of restenosis. The findings show that the combination of ET receptor antagonists and $\alpha_v\beta_3$ integrin receptor antagonists re-

present a more effective means of preventing restenosis than treatment with either drug alone. In fact, given the higher predictive value of the pig restenosis model, the in vitro results suggest effective prevention of human restenosis with combinations of ET receptor antagonists and $\alpha_v\beta_3$ integrin receptor antagonists only, rather than monotherapy.

The study was performed in land race pigs applying PTCA only or PTCA plus implantation of a stent in the LAD according to standard clinical protocols. 5 minutes prior to balloon inflation an ET_A receptor antagonist an $\alpha_v\beta_3$ integrin receptor antagonist or a combination thereof was administered intravenously and after recovery from anaesthesia the animals received the compound/s orally, subcutaneously or by continuous infusion for 4 or 12 weeks. At the end of the experiments the LAD was excised and frozen to allow receptor distribution studies and histological examination with assessment of intimal hyperplasia after angioplasty by determination of residual lumen and the neointima/media ratio.

Detailed in vivo Method:

20 Animals: Species: domestic pig
 Sex: male and female
 Age: 8 to 9 weeks
 Weight: 20 to 30 kg

Breeder: Dortans, Schatthausen, Germany. The health status of the animals used is controlled by a veterinary surgeon. Before start of the experiment, animals are acclimatized for at least 1 week. During this period the animals are trained to receive a small amount of food (mashed potatoes) before they are fed their standard maintenance diet (Ssniff Spezialdiäten GmbH, Soest), so that the drug containing mixture is quantitatively eaten by each animal within a few minutes. Drinking water is available ad libitum.

35 Study design:

40 pigs of both sexes are allocated at random to one of the following treatment groups:

1. control

40 2. $\alpha_v\beta_3$ integrin receptor antagonist: in a range between 0.05 and 5 mg/kg/d s.c. or as an iv infusion between 0,01 and 1 mg/kg/h.
3. ET_A receptor antagonist in a range between 0.1 and 50 mg/kg/d p.o.

4. ET_A receptor antagonist plus integrin $\alpha_v\beta_3$ antagonist [in a ratio between 1 : 10 and 10 : 1 and a total dosis range between 0.1 and 50 mg/kg/d p.o. or 5 mg/kg/d s.c. or 0,01 to 1 mg/kg/h infusion]

5

administration: once daily between 07:00 and 9:00 a.m. subcutaneously or orally, by giving freshly prepared mashed potatoes mixed with a calculated amount of drug.

10 Duration of treatment: 4 or 12 weeks, beginning one day before angioplasty.

All animals will receive an i.v. bolus injection of a tenth of the oral dose just before the angioplasty

15

Experimental procedure : 24 h before surgical intervention, the animals are given 650 mg acetylsalicylic acid (ASS, Ratiopharm) and 30 mg nifedipine orally in addition to the test substance or placebo. For introduction and maintenance of general anaesthesia during angioplasty, the animals are given 2 mg/kg stresnil® i.m. (Azaperon), followed by 4 mg/kg metomidat® i.v. (Hypnodil, Janssen). Animals are intubated (Rüsch Mikrolaryngealtubus, I.D.: 4.0 mm) and ventilated with 75% N₂O and 25 % O₂ . An 8F sheath (Cor-dis, FI 33102-5700) is placed retrogradely in the right carotid artery. Adequate anticoagulation is achieved by intraarterial bolus injection of 7000 IU of unfractionated heparin (Thrombophob®, Nordmark, Uetersen). A standard PTCA guide catheter (Judkin left, powerbase 8F, ACS; mandrin = softguide, soft type, ACS) is then advanced via the aortic root into the left coronary artery under X-ray guidance. The balloon catheter (RX Elipse 0.014, ACS) is positioned in the first third of the left coronary artery using a 0.014'' PTCA guide wire (Galeo, Biotronic, Berlin). After X-ray control of its position, the balloon catheter is expanded by inflating the balloon twice to 10 atm for 30 sec. After deflating the balloon and after withdrawing it, an additional angiogram is made to verify the lesion.

Specimen collection: 28 or 92 days after balloon angioplasty the animals are anaesthetized as described above. Thereafter the animals receive a relaxant (Impretil®, hexacarbocholinbromide, 0.03 mg/kg i.v.), the chest is opened and the heart removed. The dilated coronary artery segments including the adjacent noninjured segments are then carefully dissected from the epicardial surface, transferred into PBS and tissue tek is injected into the artery. After freezing the artery is sectioned transversely into 4 mm pieces. 4 sections from each segment are used for analysis

20

(determination of area media, intima and lumen)after staining with hematoxylin-eosin (HE).

5 The cross sectional area of each segment is determined with digital morphometry. Neointimal thickness is determined as difference of the residual lumen area from the total area within the internal elastica lamina, which is considered as the normal lumen area. An uninjured proximal and distal segment of 4 mm length each was used as a reference lumen.

10

Parameters measured: Incidence of acute events (acute myocardial infarction, death, cardiac arrhythmia, coronary artery spasm, arterial dissection, haematoma), neointimal-, lumen-, media-, and adventitial area and mean thickness to be determined in 4 mm intervals of the dilated area. Angiographic lumen diameter before and after balloon inflation and at the end of the 28 or 29 day treatment period.

20 Evaluation: Results are expressed as mean \pm SEM or as median. Comparisons between groups are made using Dunnett's test for unpaired samples. Correlations between injury score and neointima formation are used to compare the effect of different treatments.

25 The use of the combination of an endothelin blocker and an $\alpha_v\beta_3$ integrin receptor antagonists achieves a reduction of restenosis significantly more pronounced then one of the two treatments alone at the given doses. The combination of an ET blocker and an $\alpha_v\beta_3$ integrin receptor antagonists in doses too low to be effective alone is effective as a high mono-therapy with either agent
30 and has less potential for side-effects than one principle alone.

35

40

45

Claims

1. Use of an endothelin blocker in combination with an $\alpha_v\beta_3$ integrin receptor antagonist for the manufacture of medicaments for the treatment or prevention of diseases.
2. Use as claimed in claim 1 for the treatment or prevention of cardiovascular disorders.
3. Use as claimed in claim 2 for the treatment or prevention of restenosis after vessel injury or revascularisation treatment.
4. Pharmaceutical composition, comprising an endothelin blocker and an $\alpha_v\beta_3$ integrin receptor antagonist.
5. Composition as claimed in claim 4 for use as a medicament.
6. Composition as claimed in claim 5 for curing cardiovascular disorders.
7. Use of a composition as claimed in claim 4 for the manufacture of a medicament for the treatment or prevention of diseases.
8. Use as claimed in claim 7 for the treatment or prevention of cardiovascular disorders.
9. Use as claimed in claim 8 for the treatment or prevention of restenosis after vessel injury or revascularisation treatment.
10. Trade package, comprising as pharmaceutical agent an endothelin blocker or/and an $\alpha_v\beta_3$ integrin receptor antagonist together with an instruction for use of this pharmaceutical agents in combination for simultaneous, separate, or temporal graduated application for the treatment or prevention of diseases.

Inhibitors of the Endothelin Signalling Pathway and $\alpha_v\beta_3$ Integrin receptor antagonists for Combination Therapy

5 Abstract

The invention relates to the use of an endothelin blocker in combination with an $\alpha_v\beta_3$ integrin receptor antagonist for the treatment or prevention of diseases, particularly to the use of a pharmaceutical composition, comprising an endothelin blocker and an $\alpha_v\beta_3$ integrin receptor antagonist, for the treatment or prevention of cardiovascular disorders, particularly for the treatment or prevention of restenosis after vessel injury or revascularisation treatment and to the pharmaceutical composition itself.

15

20

25

30

35

40

45

DECLARATION AND POWER OF ATTORNEY

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name.

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

INHIBITORS OF THE ENDOTHELIN SIGNALLING PATHWAY AND $\alpha_v\beta_3$
INTEGRIN RECEPTOR ANTAGONISTS FOR COMBINATION THERAPY

the specification of which:

[] is attached hereto.

[x] was filed on _____ as Ser. No. 10/089,146

[x] was filed as PCT/EP00/09671 on October 2, 2000

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above.

[] In compliance with this duty, attached is an information disclosure statement.

I acknowledge the duty to disclose information which is material to the examination of this application in accordance with Title 37, Code of Federal Regulations, § 1.56.

I hereby claim foreign priority benefits under Title 35, United States Code, § 119 of any foreign application(s) for patent or inventor's certificate listed below and have also identified below any foreign application for patent or inventor's certificate having a filing date before that of the application on which priority is claimed:

Prior Foreign Application(s)			Priority Claimed	
			Yes	No
<u>199 48 269.1</u>	<u>Germany</u>	<u>10/6/99</u>	[X]	[]
Number	Country	Date Filed		
<u>199 62 998.6</u>	<u>Germany</u>	<u>12/24/99</u>	[X]	[]
Number	Country	Date Filed		
<u>100 27 514.1</u>	<u>Germany</u>	<u>06/06/00</u>	[X]	[]
Number	Country	Date Filed		
<u>100 28 579.9</u>	<u>Germany</u>	<u>06/14/00</u>	[X]	[]
Number	Country	Date Filed		
<u>100 39 998.3</u>	<u>Germany</u>	<u>08/11/00</u>	[X]	[]

I hereby claim the benefit under Title 35, United States Code, § 120 of any United States application(s) listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by the first paragraph of Title 35, United States Code, § 112, I acknowledge the duty to disclose material information as defined in Title 37, Code of Federal Regulations, § 1.56 which occurred between the filing date of the prior application and the national or PCT international filing date of this application:

~~CUSTOMER # 36474~~

I hereby appoint KEIL & WEINKAUF their attorneys and/or agents: Herbert B. Keil, Reg. No. 18,967; Russell E. Weinkauf, Reg. No. 18,495; Gerald H. Bjorge, Reg. No. 32,386; Norman G. Torchin, Reg. No. 34,068; Henry R. Jiles, Reg. No. 32,677; Jason D. Voight, Reg. No. 42,205; George F. Helfrich, Reg. No. 22,350; Ronald H. Smith, Reg. No. 43,679; David C. Liechty, Reg. No. 48,692, the address of all being KEIL & WEINKAUF, 1101 Connecticut Avenue, N.W., Suite 620, Washington, D.C. 20036 (telephone (202)659-0100), with full power to prosecute this application and transact all business in the Patent Office connected therewith.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Full name of first or sole inventor

Date

German
Citizenship

Rastatter, Str. 55, - 68239 Mannheim, Germany
Post Office Address

Andreas KLING

Full name of second inventor

Inventor's signature

Date _____

Residence

Citizenship

Post Office Address

Full name of second inventor

Inventor's signature


Date _____

Residence

Citizenship

Post Office Address

United States Patent & Trademark Office
Office of Initial Patent Examination -- Scanning Division



Application deficiencies found during scanning:

☒ Page(s) _____ of Abstract ^{was} ~~were~~ not present
for scanning. (Document title)

☐ Page(s) _____ of _____ were not present
for scanning. (Document title)

☐ *Scanned copy is best available.*